Outcome in APL patients treated with ATRA-based regimens (series of more than 100 cases) since 2002 in different countries
| Year . | Country . | Reporter and reference no. . | n . | CR, % . | DFS, % . | OS, % . |
|---|---|---|---|---|---|---|
| 2002 | United States | Tallman et al25 | 350 | ATRA: 70; DA: 73 | 69 (5 y) | 69 (5 y) |
| 29 (5 y) | 45 (5 y) | |||||
| 2003 | France | Bourgeois et al27 | 576 | 92.5 | 77∼84 (5 y) | |
| 2003 | Italy | Avvisati et al28 | 807 | 94.3 | EFS (n=268): 70 (5 y) | |
| 2003 | Australia | Iland37 | 101 | 90 | 88 (5.7 y) | |
| 2004 | Spain | Sanz et al29 | 426 (79*) | 90 | 81 (3 y, LPA96), 90 (3 y, LPA99), 86 (6 y*) | |
| 2006 | Brazil | Jacomo et al38 and Ribeiro et al39 | 148 | Mean OS of 133 pts: 1.7 y; excluding early mortality: 2.3 y | ||
| 2007 | Japan | Asou et al30 | 283 | 94 | 68.5 (6 y) | 83.9 (6 y) |
| Year . | Country . | Reporter and reference no. . | n . | CR, % . | DFS, % . | OS, % . |
|---|---|---|---|---|---|---|
| 2002 | United States | Tallman et al25 | 350 | ATRA: 70; DA: 73 | 69 (5 y) | 69 (5 y) |
| 29 (5 y) | 45 (5 y) | |||||
| 2003 | France | Bourgeois et al27 | 576 | 92.5 | 77∼84 (5 y) | |
| 2003 | Italy | Avvisati et al28 | 807 | 94.3 | EFS (n=268): 70 (5 y) | |
| 2003 | Australia | Iland37 | 101 | 90 | 88 (5.7 y) | |
| 2004 | Spain | Sanz et al29 | 426 (79*) | 90 | 81 (3 y, LPA96), 90 (3 y, LPA99), 86 (6 y*) | |
| 2006 | Brazil | Jacomo et al38 and Ribeiro et al39 | 148 | Mean OS of 133 pts: 1.7 y; excluding early mortality: 2.3 y | ||
| 2007 | Japan | Asou et al30 | 283 | 94 | 68.5 (6 y) | 83.9 (6 y) |
DFS indicates disease-free survival; OS, overall survival; DA, daunorubicin and cytarabine; EFS, event-free survival; and pts, patients.
Low risk (WBC count <10 × 109/L; platelet count >40 × 109/L). LPA96, CT in consolidation therapy. LPA99, CT+ATRA in consolidation therapy.